tenofovir has been researched along with Koch's Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ake, JA; Bahemana, E; Cavanaugh, JS; Crowell, TA; Dear, N; Esber, AL; Ganesan, K; Iroezindu, M; Kibuuka, H; Maswai, J; Mwesigwa, R; Owuoth, J; Parikh, AP; Polyak, CS; Reed, D; Shah, N; Singoei, V | 1 |
| Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y | 1 |
| Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C | 1 |
| Boucherie, C; Breton, G; Bugault, F; Chakrabarti, LA; Chêne, G; Cumont, MC; Lortholary, O; Patey, O; Richert, L; Roussillon, C | 1 |
| Assuied, A; De Castro, N; Fagard, C; Grinsztejn, B; Grondin, C; Molina, JM; Pilotto, JH; Sauvageon, H; Taburet, AM; Veloso, V | 1 |
| Boucherie, C; Breton, G; Caumes, E; Chaix, ML; Chêne, G; Fagard, C; Lortholary, O; May, T; Molina, JM; Padoin, C; Patey, O; Rami, A; Robert, J; Roussillon, C; Tod, M; Veziris, N | 1 |
| Abraham, P; Mancama, D; Martinson, N; Motlhaoleng, K; Naicker, S; Seedat, F; Variava, E | 1 |
| Naidoo, P; Soorju, V | 1 |
| Brown, LB; Eron, JJ; Hosseinipour, MC; Kumwenda, JJ; Mhango, B; Mzinganjira, D; Phiri, S; van Oosterhout, JJ; Weigel, R | 1 |
| Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Chalifoux, L; Chen, ZW; Enimi, EA; Gastron, M; Henckler, B; Letvin, NL; Miller, M; Sehgal, N; Sehgal, P; Shen, L; Shen, Y; Simon, M; Zhou, D | 1 |
3 trial(s) available for tenofovir and Koch's Disease
| Article | Year |
|---|---|
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Isoniazid; Lamivudine; Rifampin; RNA; South Africa; Tenofovir; Tuberculosis; Viral Load | 2023 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Brazil; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Raltegravir Potassium; Rifampin; Tenofovir; Tuberculosis | 2015 |
9 other study(ies) available for tenofovir and Koch's Disease
| Article | Year |
|---|---|
Epidemiology of Tuberculosis Among People Living With HIV in the African Cohort Study From 2013 to 2021.
Topics: CD4 Lymphocyte Count; Cohort Studies; HIV Infections; Humans; Incidence; Lamivudine; Risk Factors; Tenofovir; Thinness; Tuberculosis | 2023 |
Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lymphocyte Activation; Male; Middle Aged; Mycobacterium tuberculosis; Organophosphonates; Risk Factors; Tenofovir; Tuberculosis | 2014 |
Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2016 |
Acute Kidney Injury, Risk Factors, and Prognosis in Hospitalized HIV-Infected Adults in South Africa, Compared by Tenofovir Exposure.
Topics: Acute Kidney Injury; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Hospitalization; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Survival Analysis; Tenofovir; Tuberculosis; Young Adult | 2017 |
Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Hospitals; Humans; Lamivudine; Lipodystrophy; Male; Middle Aged; Retrospective Studies; Rural Population; South Africa; Stavudine; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load; Young Adult | 2016 |
Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Body Mass Index; CD4 Lymphocyte Count; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; HIV Infections; HIV-1; Humans; Malawi; Male; Medication Adherence; Middle Aged; National Health Programs; Organophosphonates; Prospective Studies; RNA, Viral; Statistics as Topic; Tenofovir; Treatment Failure; Tuberculosis; Urban Population; Viral Load; Zidovudine | 2010 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Ethambutol; Female; Genotype; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Middle Aged; Organophosphonates; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Tenofovir; Tuberculosis; Young Adult | 2013 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; HIV Protease Inhibitors; Indinavir; Macaca mulatta; Macaca nemestrina; Mycobacterium bovis; Nelfinavir; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocytes; Tenofovir; Tuberculosis | 2001 |